The effects of iron oxide labelling on the in vitro chondrogenic potential of three human cell types

S. Saha1, S. F. Tanner2, J. Kirkham1, D. Wood1, S. Curran3, and X. B. Yang1

1Department of Oral Biology, University of Leeds, Leeds, W-Yorkshire, United Kingdom, 2Division of Medical Physics, University of Leeds, Leeds, W-Yorkshire, United Kingdom, 3Smith and Nephew Research Centre, York, United Kingdom

Introduction: MR imaging has been used to monitor the distribution of administered cells in studies related to the use of cell therapy in regenerative medicine. Labelling cells with Super-Paramagnetic Iron Oxide (SPIO) particles makes it possible to monitor the distribution of these cells within images showing the tissue [1]. There has been disagreement on the effects of this label on cellular differentiation and in particular on development along the chondrogenic lineage [2-3]. Almost all previous studies have employed staining to infer cartilage formation. This study has used the quantitative reverse transcription polymerase chain reaction (qRT-PCR) technique to assess potential affects of the SPIO on chondrogenic gene expression of three different cell types exposed to chondroinductive media for different time periods.

Methods: Measurements were made in Human Bone Marrow Stem Cells (HBMSC), adult chondrocytes and neonatal chondrocytes. All three cell types were labelled with SPIO (Resovist - Schering, Berlin) for 24 hours with an incubation concentration of 0.5 nmol Fe/ml (1μl/ml culture media) at 37°C and 5% CO2. A transfection agent was not added and labelling was carried out in a serum free culture medium [4]. After removal of extracellular SPIO, prussian blue staining confirmed the presence of iron within the cells. Chondrogenesis was induced by incubating the cells with a serum free medium consisting of αMEM supplemented with 10 ng/ml TGF-β3, 10-8 M dexamethasone, 100 μM ascorbate-2-phosphate and 1x ITS supplement. In vitro chondrogenesis was examined using RT-PCR for all 3 cell types in both SPIO labelled and unlabelled cells after 2, 7 and 14 days exposure to the chondrogenic media. Relative quantification of Sox9 (SOX9), Collagen type II (COL2A1) and aggrecan (ACAN) gene expression levels in the labelled cells was determined by normalising them to the expression levels in unlabelled cells at the same time point.

Results: Real time RT-PCR revealed differences in expression of SOX9, ACAN and COL2A1 both with time and between the cell types. HBMSCs and adult chondrocytes showed normal levels of ACAN but a significant relative decrease in the expression of SOX9 and COL2A1 in the labelled cells after 2 days culture (Fig 1). After 7 and 14 days these cells showed no significant differences between labelled and unlabelled cells in the expression of SOX9, ACAN and COL2A1. For neonatal chondrocytes, labelling resulted in a decrease in ACAN expression after 2 days that recovered to near normal levels by day 7 and then showed another relatively marked decrease after 14 days of exposure to the chondroinductive media.

Discussion: This study is the first to show that inhibition of gene expression for chondrogenic markers resulting from SPIO labelling is dependent on the target cell used. Whilst HBMSCs and adult chondrocytes show a short term effect due to the label, Resovist does not affect marker gene expression in these cells after approximately 7 days of chondroinductive culture. Neonatal chondrocytes show very different behaviour in that the effect of the Resovist label is still evident on ACAN expression at relatively long periods after exposure to the chondroinductive media. The nature of this interference to the chondrogenic pathway in the neonatal cells is unknown. Although this study has not measured the cellular SPIO concentrations, it does indicate that Resovist can be used to label bone marrow stem cells or mature chondrocytes in MR imaging studies of cartilage repair or regeneration.